AZN vs GELS

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

GELS exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis. While the company shows strong top-line revenue growth (59.40%) and healthy gross margins (72.07%), these are completely offset by a catastrophic operating margin of -2969.43%. With a current ratio of 0.27 and a quick ratio of 0.14, the company lacks the liquidity to meet its short-term obligations. Despite trading below book value (P/B 0.70), the fundamental instability and long-term price decay make this a high-risk speculative asset.